What we do Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) and provides contract development and manufacturing services globally. |
Founded in 1,984 |
Market share A leading contract development and manufacturing organization (CDMO) with a strong presence in generic APIs across 80+ countries. |
Problem solved Addresses pharmaceutical supply needs by providing complex and specialized APIs and contract manufacturing services to innovators and generic drug makers. |
Top clients or who we serve Serves innovator pharmaceutical companies and generic manufacturers globally across North America, Europe, and Asia (B2B). |
Key management Executive Chairman Dr. Davuluri Rama Mohan Rao, CEO Sucheth Rao, and Managing Director Saharsh Rao lead the company. |
Our journey and innovations Established in 1984, pioneer in bulk drugs; introduced novel APIs and peptides; expanded manufacturing capacity; strategic mergers and global expansions. |
Where we operate Operates manufacturing units in India with business development offices in USA and Japan, serving over 80 countries worldwide. |
Top products or what we offer Offers 100+ APIs, including Salbutamol Sulphate, Terbutaline Sulphate, specialty peptides, and custom manufacturing for clinical and commercial drug substances. |
Top brands Key API products include Salbutamol Sulphate, Terbutaline Sulphate, Itraconazole, Ramipril; recognized for peptide APIs and CMS business. |
Raw materials needed Requires various chemical intermediates for API synthesis, including specialized reagents and raw chemicals for advanced peptide synthesis. |
Raw materials supplier Sources raw materials from qualified chemical suppliers domestically and internationally, maintaining robust supply chain management. |
Recurring vs cyclical contribution Revenue is a mix of recurring generic API sales and cyclical contract manufacturing projects depending on clinical and commercial phases. |
Our industry position Among the top CDMOs in India with a diversified portfolio, known for quality and regulatory compliances, holding numerous global DMFs. |
Financial highlights FY24 revenue Rs.1497 crore, PAT Rs.260 crore; recent quarters show stable income with focus on margin improvement amid investments. |
Geographical revenue split Revenue split roughly India 29%, Europe 29%, USA & North America 28%, rest of world 10% approximately. |
Order book Strong order pipeline from innovator customers with over 75 active CMS projects and increasing peptide API engagements. |
Whats driving growth Growth driven by CMS engagements with innovators, peptide API market expansion, R&D investments, and global regulatory approvals. |
Our future plans Capex for R&D facility expansion, increased peptide API production, and enhancing contract manufacturing capabilities. |
Our green promise Committed to sustainability with goals for emission reductions, zero liquid discharge, water neutrality, and green chemistry adoption. |
Our people and values Over 2100 employees including 428 R&D scientists; focused on talent pipeline, diversity, and employee engagement. |
Key challenges ahead Managing lifecycle transitions in CMS revenues, margin pressures, regulatory compliance, and global supply chain risks. |
Interesting facts First Indian peptide API manufacturer to file a peptide Drug Master File; operates largest reactor capacity among Indian CDMOs. |
Risks and strategy Strategic focus on quality, innovation, and customer-centricity to mitigate competitive and regulatory risks, supported by enterprise risk management. |
